Colorectal cancer (CRC) continues to represent one of the most formidable challenges in oncology, ranking among the leading causes of cancer-related deaths globally. Despite advances in detection and treatment, therapeutic options remain limited, particularly in targeting the inflammatory signaling pathways that drive disease progression. Central to these pathways is glycoprotein 130 (gp130), a transmembrane signal-transducing receptor shared by the interleukin-6 (IL-6) cytokine family. Aberrant activation of gp130 stimulates downstream oncogenic cascades, notably the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway, which fosters tumor cell survival, proliferation, and resistance to apoptosis. Yet, despite its critical role, gp130 remains a comparatively underexploited target in anticancer drug development, primarily due to the scarcity of potent and selective inhibitors.
Addressing this unmet need, a multinational research team spearheaded by Professors Wenying Yu and Yixian Liao from China Pharmaceutical University has unveiled a groundbreaking drug discovery strategy employing artificial intelligence-driven transfer learning. This synergistic approach overcomes the classical bottlenecks inherent in the identification of novel gp130 antagonists, notably the limited availability of bioactive candidate compounds that often hampers machine learning model training. By harnessing transfer learning, the researchers initially trained a predictive computational framework on a robust dataset comprising known STAT3 inhibitors—a key downstream effector of the gp130 axis—and subsequently refined the model using a narrowly curated collection of verified gp130 inhibitors. This two-stage training paradigm enabled the high-throughput virtual screening of a diverse chemical library comprising 2,560 natural products.
Crucially, the screening process incorporated rigorous filters not only on absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles but also on molecular complexity metrics, including the medicinal chemistry evolution score (MCE-18), to prioritize structurally novel and drug-like candidates. Through this meticulous pipeline, evodiamine emerged as a promising scaffold, known for its bioactivity yet amenable to structural optimization. Guided by medicinal chemistry principles focusing on rational hybridization, a suite of indolopyridine derivatives was synthesized, culminating in the identification of Compound 8a as the lead candidate with superior pharmacological properties.
Biophysical interrogation using techniques such as surface plasmon resonance and isothermal titration calorimetry established that Compound 8a binds directly to the D1 domain of gp130 with a dissociation constant (K_D) of 2.17 μM. This affinity markedly surpasses that of comparative compounds including evodiamine, rutaecarpine, and the clinically utilized gp130 inhibitor bazedoxifene. Mechanistic studies elucidated that 8a selectively obstructs gp130-mediated phosphorylation events of JAK2 and STAT3, effectively disrupting STAT3’s DNA-binding capacity and downstream transcriptional activation of oncogenes like Bcl-2 and Cyclin D1, which are instrumental in promoting cell survival and cell cycle progression.
Functional validation in colorectal cancer cell lines, specifically HT-29 cells, demonstrated that Compound 8a exerts potent antiproliferative effects coupled with induction of mitochondrial apoptosis. Notably, these anticancer effects showed dependency on gp130 expression levels, underscoring the compound’s mechanism-specific action. Extending these findings in vivo, oral administration of Compound 8a at 20 mg/kg in HT-29 xenograft mouse models resulted in a remarkable 56.20% inhibition of tumor growth. Importantly, this antitumor efficacy transpired without discernible systemic toxicity, signifying a favorable therapeutic window that outperformed bazedoxifene under analogous experimental conditions.
Complementing these efficacy studies, preliminary pharmacokinetic evaluations revealed improved metabolic stability of Compound 8a in rat liver microsomes relative to evodiamine, indicating enhanced drug-like properties and potential for further clinical translation. This pharmacokinetic advantage derives from structural modifications enhancing metabolic resistance while preserving target affinity. The collective data establish Compound 8a as a structurally innovative molecule with a mechanistically distinct mode of action, positioning it as a compelling gp130-targeted therapeutic candidate.
The broader implications of this research highlight the power of artificial intelligence, particularly transfer learning strategies, in accelerating the discovery of novel drug candidates amid data scarcity—a pervasive challenge in targeted oncology. This methodology provides a blueprint for extending similar approaches to other understudied cytokine receptors and signaling nodes implicated in diverse malignancies and inflammatory disorders. Beyond revealing a new antitumor agent, this study advances a paradigm wherein computational intelligence complements experimental pharmacology to surmount traditional hurdles in drug discovery.
As colorectal cancer continues to exact a high mortality toll, innovations such as Compound 8a offer hope for more effective treatment modalities by specifically dismantling the pathological signaling pathways fundamental to tumor progression. Future investigations encompassing detailed pharmacodynamics, optimized formulation development, and clinical evaluation will be pivotal in translating these promising preclinical findings into tangible patient benefits. Moreover, this work underscores the expanding horizon of AI-enabled precision medicine, foreshadowing a new era of rational drug design driven by integrative data science and molecular biology.
This landmark study, titled “Transfer learning algorithm assisted in the discovery of novel gp130 inhibitors and their application in colorectal cancer treatment,” was published online on March 20, 2026, in the journal Targetome. It exemplifies the confluence of cutting-edge computational methods and rigorous experimental validation, setting a new standard for target-directed anticancer drug discovery.
Subject of Research: Not applicable
Article Title: Transfer learning algorithm assisted in the discovery of novel gp130 inhibitors and their application in colorectal cancer treatment
News Publication Date: 20-Mar-2026
Web References: http://dx.doi.org/10.48130/targetome-0026-0010
Image Credits: HIGHER EDUCATION PRESS
Keywords: colorectal cancer, gp130, JAK2/STAT3 signaling, transfer learning, drug discovery, natural products, indolopyridine derivatives, Compound 8a, evodiamine, ADMET, pharmacokinetics, mitochondrial apoptosis
Tags: AI-driven transfer learning for drug discoverycolorectal cancer therapeutic targetscomputational modeling in oncologygp130 inhibitors for colorectal cancerJAK2/STAT3 signaling inhibitionmachine learning in cancer treatmentmultinational cancer research collaborationnovel anticancer drug developmentovercoming limited bioactive compound datasetsselective gp130 antagonist identificationsynergy of AI and pharmacologytargeting IL-6 cytokine family pathways
